Our approach

Our discovery and development teams are working to find a biomarker driven therapy for a functional cure of chronic hepatitis B.

We employ engineered bionanoparticles (BNPs) of hepatitis B surface antigen (HBsAg) delivering clearance epitope target inserts.

CLB-3000-01-001 is currently enrolling, click the button below for Clinical trial information.

ACTRN12623000841673

ClearB is committed to developing a cure for patients chronically infected with hepatitis B.

Our work is grounded in proprietary insights derived from studying rare-event infection resolution in patients who suffer from chronic hepatitis B.

Predicting HBsAg clearance in genotype A chronic hepatitis B using HBsAg epitope profiling: A biomarker for functional cure

Read paper

The World Health Organisation defines hepatitis B as “a potentially life-threatening liver infection caused by the hepatitis B virus (HBV). It is a major global health problem. It can cause chronic infection and puts people at high risk of death from cirrhosis and liver cancer.”

At ClearB, we are working to develop immunotherapies which harness the bodies’ natural immune system to result in a functional cure for chronic hepatitis B (CHB).

  • Approx. 2 billion people are infected with HBV and ~250 million living with chronic hepatitis B (CHB) virus infection

  • Viral hepatitis is the 7th ranked cause of human death

  • 15-25% of people with CHB develop advanced liver disease &/or HCC (without appropriate clinical management)

  • Liver cancer is the 3rd most common cause of cancer death globally